• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xenetic Biosciences, Inc. - Common Stock (NQ:XBIO)

4.260 -0.130 (-2.96%)
Streaming Delayed Price Updated: 3:19 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Xenetic Biosciences, Inc. - Common Stock

< Previous 1 2 3 Next >
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock
October 10, 2025
Via ACCESS Newswire
MAGA Stocks Undercard: MYSE, XBIO, ATON, ACXP, RDZN – Innovators Driving Next Tech, Blockchain, AI Wave – More Stocks Inside
October 08, 2025
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results
August 13, 2025
Via ACCESS Newswire
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma
July 30, 2025
Via ACCESS Newswire
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
December 17, 2024
Via ACCESSWIRE
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
November 22, 2024
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
November 13, 2024
Via ACCESSWIRE
Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
July 23, 2025
Via ACCESS Newswire
Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic
July 08, 2025
Via ACCESS Newswire
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
May 14, 2025
Via ACCESS Newswire
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
April 09, 2025
Via ACCESS Newswire
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma
March 26, 2025
Via ACCESS Newswire
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
November 07, 2024
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024
Via ACCESSWIRE
Xenetic Biosciences, Inc. Announces Executive Leadership Transition
May 22, 2024
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
March 19, 2025
Via ACCESS Newswire
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses
March 13, 2025
Via ACCESS Newswire
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
February 27, 2025
Via ACCESS Newswire
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
December 16, 2024
Via ACCESSWIRE
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
December 05, 2024
Via ACCESSWIRE
Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
October 11, 2023
Via ACCESSWIRE
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
November 21, 2024
Via ACCESSWIRE
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
November 12, 2024
Via ACCESSWIRE
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
October 22, 2024
Via ACCESSWIRE
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
October 17, 2024
Via ACCESSWIRE
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
September 11, 2024
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
May 10, 2024
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
March 22, 2024
Via ACCESSWIRE
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
January 17, 2024
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results
November 10, 2023
Via ACCESSWIRE
< Previous 1 2 3 Next >
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap